MAG
XGN icon

Millrace Asset Group’s Exagen XGN Stock Holding History

Millrace Asset Group’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-67,235
Closed -$1.07M – 87
2020
Q1 		$1.07M Buy
67,235
+5,435
+9% +$108K 1.62% 29
2019
Q4 		$1.57M Sell
61,800
-8,200
-12% -$146K 1.71% 26
2019
Q3 		$1.08M Buy
+70,000
New +$1.13M 1.27% 43

Other funds holding XGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millrace Asset Group's XGN Position: Q2 2020 in Review

Millrace Asset Group sold out of Exagen (XGN) in Q2 2020, closing a stake of 67,235 shares — an estimated $1.07M sold.

Millrace Asset Group first reported a position in XGN in Q3 2019 and held it in 3 quarters. The position peaked at $1.57M in Q4 2019. 34 funds tracked by Wall St. Rank hold XGN as of Q2 2020.

  • Millrace Asset Group reported no remaining Exagen position as of Q2 2020 after selling out during the quarter.
  • Millrace Asset Group sold 67,235 Exagen shares in Q2 2020, an estimated $1.07M.
  • Millrace Asset Group first reported a position in Exagen in Q3 2019 and held it in 3 quarters.
  • Millrace Asset Group's Exagen position peaked at $1.57M in Q4 2019.
  • 34 funds tracked by Wall St. Rank held Exagen as of Q2 2020.

Based on Millrace Asset Group's 13F filing for Q2 2020, filed 13 Aug 2020.